Denali Therapeutics (DNLI) Cash from Investing Activities (2017 - 2025)
Historic Cash from Investing Activities for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $57.8 million.
- Denali Therapeutics' Cash from Investing Activities fell 3825.21% to $57.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $406.7 million, marking a year-over-year increase of 31643.71%. This contributed to the annual value of -$88.8 million for FY2024, which is 13560.09% down from last year.
- As of Q3 2025, Denali Therapeutics' Cash from Investing Activities stood at $57.8 million, which was down 3825.21% from $157.9 million recorded in Q2 2025.
- Denali Therapeutics' 5-year Cash from Investing Activities high stood at $172.2 million for Q4 2024, and its period low was -$453.2 million during Q1 2024.
- In the last 5 years, Denali Therapeutics' Cash from Investing Activities had a median value of $57.8 million in 2025 and averaged $12.2 million.
- In the last 5 years, Denali Therapeutics' Cash from Investing Activities skyrocketed by 55444.58% in 2023 and then crashed by 38879.58% in 2024.
- Quarter analysis of 5 years shows Denali Therapeutics' Cash from Investing Activities stood at -$40.8 million in 2021, then tumbled by 213.03% to -$127.6 million in 2022, then soared by 157.27% to $73.0 million in 2023, then surged by 135.75% to $172.2 million in 2024, then crashed by 66.42% to $57.8 million in 2025.
- Its Cash from Investing Activities was $57.8 million in Q3 2025, compared to $157.9 million in Q2 2025 and $18.7 million in Q1 2025.